Discovery Biology

Evaluates the effects of drug candidates on fertility, embryonic development, and postnatal outcomes. Studies are designed to assess teratogenicity, maternal

Inhalation Dermal Ophthalmic Routes Conducted to assess systemic and local toxicity based on intended route of administration. Provides vital data

Performs microscopic examination of tissues and organs to identify structural or cellular alterations linked to compound exposure. This provides crucial

Evaluates the safety of impurities, degradation products, and unique metabolites in line with ICH M7 and FDA guidance. Ensures that

In-Vivo Genotoxicity Tests Long-Term Carcinogenicity Studies Assesses mutagenic, clastogenic, and carcinogenic potential of test substances under prolonged exposure. These studies

Acute, Subacute & Repeat-Dose Toxicity (14/28/90-Day) Rodent and Non-Rodent Models Evaluates systemic effects, target organ toxicity, and dose-dependent responses over

Ames Test In-Vitro Micronucleus Chromosomal Aberration Assays Screens for mutagenic potential using bacterial and mammalian cell-based assays. These early-stage tests

In-Vitro CYP Induction/Inhibition Assays Transporter Interaction Panels (P-gp, BCRP, OATP) Follow-Up In-Vivo Confirmation Studies Identifies metabolic and transporter-based drug–drug interactions,

GLP-Compliant LC-MS/MS Capabilities Biostatistics, Data Analysis, and PK/PD Modelling Provides validated quantitative bioanalysis of drug and metabolite levels with expert

ELISA and Multiplex Immunoassays Proteomic Readouts and Clinical Pathology Panels Develops and validates biomarker and PD assays that quantify biological